Literature DB >> 1338000

Ribonucleotide diphosphate reductase from human metastatic melanoma.

K U Schallreuter1, T E Elgren, L S Nelson, S MacFarlan, I Yan-Sze, H P Hogenkamp.   

Abstract

Cell free extracts from metastases of human melanoma contain a highly active ribonucleoside diphosphate reductase (RR) which uses guanosine diphosphate (GDP) as substrate and deoxythymidine triphosphate (dTTP) as effector. No activity could be detected in these extracts when cytidine diphosphate (CDP) was used as the substrate with adenosine triphosphate (ATP) as effector. The activity of this RR required the presence of either magnesium or calcium: there was a time lag before cell extracts from melanotic melanoma metastases showed full activities, but extracts from amelanotic tumors showed normal kinetics in the presence of these divalent cations. By contrast to other RRs, the activities in cell-free extracts could not be inhibited by hydroxyurea (10(-2) M). Even though an activity related free radical could be detected by electron paramagnetic resonance spectroscopy at 77 degrees K, the signal could not be quenched by 10(-2) M of this free radical trap. However, after ammonium sulphate fractionation, enzyme activity from melanotic melanoma was inhibited by 66% in 1 h. In the presence of substrates, effector and cofactors, the radical signal at g = 2.009 was also quenched by 60%; in the absence of substrate, effectors and cofactors, this signal was unaffected. These results indicate that two different free radicals must be present on melanoma RR. One is present in the resting enzyme, and the other is used during catalytic activity. The thiolate-active site of RR from melanoma was inhibited by the new nitrosourea anti-tumour drug fotemustine (IC50 = 10(-4) M as determined from a dose-response study).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1338000     DOI: 10.1097/00008390-199212000-00014

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  4 in total

Review 1.  Current progress of siRNA/shRNA therapeutics in clinical trials.

Authors:  John C Burnett; John J Rossi; Katrin Tiemann
Journal:  Biotechnol J       Date:  2011-07-11       Impact factor: 4.677

2.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.

Authors:  B S Zhou; P Tsai; R Ker; J Tsai; R Ho; J Yu; J Shih; Y Yen
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 4.510

3.  Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.

Authors:  Keqiang Zhang; Shuya Hu; Jun Wu; Linling Chen; Jianming Lu; Xiaochen Wang; Xiyong Liu; Bingsen Zhou; Yun Yen
Journal:  Mol Cancer       Date:  2009-02-28       Impact factor: 27.401

4.  Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.

Authors:  J Souglakos; I Boukovinas; M Taron; P Mendez; D Mavroudis; M Tripaki; D Hatzidaki; A Koutsopoulos; E Stathopoulos; V Georgoulias; R Rosell
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.